Access links:
Access links:
J Immunol. 2012 Jun 15;188(12):6036-45. Epub 2012 May 11
AbstractDuring HIV-1 infection, dendritic cells (DC) facilitate dissemination of HIV-1 while trying to trigger adaptive antiviral immune responses. We examined whether increased HIV-1 capture in DC matured with LPS results in more efficient Ag presentation to HIV-1-specific CD4(+) and CD8(+) T cells. To block the DC-mediated trans-infection of HIV-1 and maximize Ag loading, we also evaluated a noninfectious integrase-deficient HIV-1 isolate, HIV(NL4-3ΔIN). We showed that higher viral capture of DC did not guarantee better Ag presentation or T cell activation. Greater HIV(NL4-3) uptake by fully LPS-matured DC resulted in higher viral transmission to target cells but poorer stimulation of HIV-1-specific CD4(+) and CD8(+) T cells. Conversely, maturation of DC with LPS during, but not before, viral loading enhanced both HLA-I and HLA-II HIV-1-derived Ag presentation. In contrast, DC maturation with the clinical-grade mixture consisting of IL-1β, TNF-α, IL-6, and PGE(2) during viral uptake only stimulated HIV-1-specific CD8(+) T cells. Hence, DC maturation state, activation stimulus, and time lag between DC maturation and Ag loading impact HIV-1 capture and virus Ag presentation. Our results demonstrate a dissociation between the capacity to capture HIV-1 and to present viral Ags. Integrase-deficient HIV(NL4-3ΔIN) was also efficiently captured and presented by DC through the HLA-I and HLA-II pathways but in the absence of viral dissemination. HIV(NL4-3ΔIN) seems to be an attractive candidate to be explored. These results provide new insights into DC biology and have implications in the optimization of DC-based immunotherapy against HIV-1 infection.
Maria T. Rodriguez-Plata1, Alejandra Urrutia2, Sylvain Cardinaud2, Maria J. Buzón1, Nuria Izquierdo-Useros1, Julia G. Prado1, Maria C. Puertas1, Itziar Erkizia1, Pierre-Grégoire Coulon2, Samandhy Cedeño1, Bonaventura Clotet1, Arnaud Moris2, Javier Martinez-Picado1,3
1AIDS Research Institute IrsiCaixa, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona; 2INSERM, Unité Mixte de Recherche Scientifique 945 (UMRS-945), Infection et Immunité, Université Pierre et Marie Curie; 3Institució Catalana de Recerca i Estudis Avançats, (ICREA)
Linked groups: Retrovirology and Clinical Studies Group (GREC)